First cases of Candida auris reported in United States

Nov 09, 2016 | Kim Rodgers

Thirteen cases of Candida auris (C. auris), a serious and sometimes fatal fungal infection that is emerging globally, have been identified in the United States. Seven of the cases occurred between May 2013 and August 2016 and are described in a report released in CDC’s Morbidity and Mortality Weekly Report (MMWR). The other six cases were identified after the period covered by the report and are still under investigation.

This MMWR is the first to describe U.S. cases of C. auris infection, which is often resistant to antifungal drugs and tends to occur in hospitalized patients. In June 2016, CDC issued interim recommendations as well as a clinical alert describing the global emergence of C. auris and requesting that laboratories report C. auris cases and send patient samples to state and local health departments and CDC.

Among the seven cases detailed in the report, patients with C. auris were reported in four states: New York, Illinois, Maryland and New Jersey. All of the patients had serious underlying medical conditions and had been hospitalized an average of 18 days when C. auris was identified. Four of the patients died; it is unclear whether the deaths were associated with C. auris infection or underlying health conditions. CDC recommends that healthcare professionals implement strict Standard and Contact Precautions to control the spread of C. auris. Facilities should conduct thorough daily and after-discharge cleaning of rooms of C. auris patients with an EPA-registered disinfectant active against fungi.

CDC’s Antibiotic Resistance Laboratory Network is providing additional lab support in four regional laboratories to test fungal susceptibility of Candida species and identify emerging resistance. CDC is also expanding tracking of this fungus through the Emerging Infections Program. Information gathered through these networks play a key role in tracking resistance and informing policies and interventions. In 2013, CDC issued a report describing antibiotic resistance threats in the United States that needed prompt action, including Candida infections.

Things to Consider

  • Identifying auris requires specialized laboratory methods because it can easily be misidentified as another type of Candida infection, in which case patients may not receive appropriate treatment. Most of the patient samples in the current report were initially misidentified as another species of Candida.
  • Most of the auris strains from U.S. patients (71%) showed some drug resistance, making treatment more difficult. Samples of C. auris strains from other countries have been found to be resistant to all three major classes of antifungal medications. However, none of the U.S. strains in this report were resistant to all three antifungal drug classes.
  • In two instances, two patients had been treated in the same hospital or long-term-care facility and had nearly identical fungal strains. These findings suggest that auris could be spread in healthcare settings.

About Kim Rodgers

Pronouns: She/Her

Kim Rodgers was formerly the Communications Manager at NACCHO.

More posts by Kim Rodgers

Related Posts

D4 web

Day Four Highlights: 2024 Preparedness Summit

See highlights from the final day of the 2024 Preparedness Summit.

Mar 28, 2024

Day Four Highlights: 2024 Preparedness Summit

I Stock 1182682774
  • Adverse Childhood Experiences (ACEs)
  • Behavioral Health
  • Community Health
  • Injury and Violence Prevention

Seeking LHD Participants for an Intersectional Data...

With support from the Centers for Disease Control and Prevention, NACCHO is...

Mar 28, 2024 | Camille Adams

Seeking LHD Participants for an Intersectional Data...

Ps24 posters d3 web

Day Three Highlights: 2024 Preparedness Summit

See highlights from day three of the 2024 Preparedness Summit.

Mar 27, 2024

Day Three Highlights: 2024 Preparedness Summit

D2 highlights web

Day Two Highlights: 2024 Preparedness Summit

See highlights from day two of the 2024 Preparedness Summit.

Mar 26, 2024

Day Two Highlights: 2024 Preparedness Summit

PS24 1

Day One Highlights: 2024 Preparedness Summit

See highlights from day one of the 2024 Preparedness Summit.

Mar 25, 2024

Day One Highlights: 2024 Preparedness Summit

PS24 web
  • Tools & Resources
  • Training

Welcome to the 2024 Preparedness Summit!

Welcome to the 2024 Preparedness Summit.

Mar 25, 2024 | Beth Hess

Welcome to the 2024 Preparedness Summit!

Stakeholder Conference Call on the FDA Integrated Food...

You’re invited to join the call on April 2 to hear more.

Mar 25, 2024

Stakeholder Conference Call on the FDA Integrated Food...

Cover and Spine for MAPP 2 0 Handbook Copy Page 1
  • Mobilizing for Action through Planning and Partnerships (MAPP)
  • Performance Improvement
  • Workforce Development

Register to Attend a Mobilizing for Action through...

Registration is now open for NACCHO’s in-person Mobilizing for Action through...

Mar 23, 2024 | Andrea Grenadier

Register to Attend a Mobilizing for Action through...

Capitol bulding

Congress Releases Labor-HHS Bill in Final FY2024 Package

Early on March 21st, Congress released the final minibus package for Fiscal...

Mar 22, 2024 | Victoria Van de Vate

Congress Releases Labor-HHS Bill in Final FY2024 Package

Back to Top